Literature DB >> 9789605

Report of the European Task Force on Lymphomas: workshop on peripheral T-cell lymphomas.

E Campo1, P Gaulard, E Zucca, E S Jaffe, N L Harris, J Diebold, B Schlegelberger, A C Feller, G Delsol, C Gisselbrecht, E Montserrat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9789605     DOI： 10.1023/a:1008439620513

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  8 in total

1.  Primary colon lymphoma in Korea: a KASID (Korean Association for the Study of Intestinal Diseases) Study.

Authors:  Y-H Kim; J H Lee; S K Yang; T I Kim; J S Kim; H J Kim; J I Kim; S W Kim; J O Kim; I K Jung; S A Jung; M K Jung; H S Kim; S J Myung; W H Kim; J C Rhee; K Y Choi; I S Song; J H Hyun; Y I Min
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

2.  Diagnosis of systemic metastatic retinal lymphoma.

Authors:  Xiaoguang Cao; Defen Shen; David G Callanan; Manabu Mochizuki; Chi-Chao Chan
Journal:  Acta Ophthalmol       Date:  2011-03       Impact factor: 3.761

3.  Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.

Authors:  Owen A O'Connor; Barbara Pro; Lauren Pinter-Brown; Nancy Bartlett; Leslie Popplewell; Bertrand Coiffier; Mary Jo Lechowicz; Kerry J Savage; Andrei R Shustov; Christian Gisselbrecht; Eric Jacobsen; Pier Luigi Zinzani; Richard Furman; Andre Goy; Corinne Haioun; Michael Crump; Jasmine M Zain; Eric Hsi; Adam Boyd; Steven Horwitz
Journal:  J Clin Oncol       Date:  2011-01-18       Impact factor: 44.544

4.  Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma.

Authors:  M Casanova; A Medina-Pérez; M Moreno-Beltran; M Mata-Vazquez; A Rueda
Journal:  Ther Clin Risk Manag       Date:  2011-10-07       Impact factor: 2.423

Review 5.  Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders.

Authors:  Qingqing Cai; Kailin Chen; Ken H Young
Journal:  Exp Mol Med       Date:  2015-01-23       Impact factor: 8.718

6.  Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma.

Authors:  Patrick B Johnston; Amanda F Cashen; Petros G Nikolinakos; Anne W Beaven; Stefan Klaus Barta; Gajanan Bhat; Steven J Hasal; Sven De Vos; Yasuhiro Oki; Changchun Deng; Francine M Foss
Journal:  Exp Hematol Oncol       Date:  2021-02-18

Review 7.  Pralatrexate, a new hope for aggressive T-cell lymphomas?

Authors:  Antonio Rueda; María Casanova; Cristina Quero; Angeles Medina-Pérez
Journal:  Clin Transl Oncol       Date:  2009-04       Impact factor: 3.340

8.  Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis.

Authors:  Jung Yong Hong; Dok Hyun Yoon; Sang Eun Yoon; Seok Jin Kim; Ho Sup Lee; Hyeon-Seok Eom; Hye Won Lee; Dong-Yeop Shin; Youngil Koh; Sung-Soo Yoon; Jae-Cheol Jo; Jin Seok Kim; Soo-Jeong Kim; Su-Hee Cho; Won-Sik Lee; Jong-Ho Won; Won Seog Kim; Cheolwon Suh
Journal:  Sci Rep       Date:  2019-12-30       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.